50 completed, 9 terminated, 8 unknown, 6 recruiting. 38 Phase 4, 19 Phase 3, 15 Phase 2, 7 Not applicable, 4 Phase 1.
Follow prednisolone acetate: new trials by email Literature Review of prednisolone acetate trials Research Report on prednisolone acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) MK-1045, Rituximab, Rituximab biosimilar - Follicular Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-06-22 | 2026-10-15 |
| A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis VVN461 Ophthalmic Solution 1.0%, 1.0% prednisolone acetate - Non-infectious Anterior Uveitis | Phase 3 | Active not recruiting | VivaVision Biotech, Inc | 154 | 2025-11-25 | 2026-08-24 |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) Ifinatamab deruxtecan, Docetaxel, Prednisone - Prostate Cancer, Prostatic Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1440 | 2025-05-13 | 2026-10-15 |
| Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops - Keratoconus | Phase 1 / Phase 2 | Enrolling by invitation | Maanasa Indaram, MD | 20 | 2025-04-11 | 2026-09-11 |
| Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}, Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte} - Cataract | Phase 1 / Phase 2 | Recruiting | Inder Paul Singh, M.D. | 94 | 2024-07-10 | 2024-11-29 |
| A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Prednisolone acetate - Anterior Uveitis | Phase 2 | Completed | VivaVision Biotech, Inc | 89 | 2023-11-27 | 2025-01-27 |
| Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution - Corneal Edema, Corneal Defect | Phase 4 | Completed | Nicole Fram M.D. | 50 | 2023-06-01 | 2026-02-20 |
| Research on the Treatment of Severe Community-acquired Pneumonia in Children Prednisolone Acetate, placebo - Severe Pneumonia | Phase 4 | Unknown | Baoping XU | 160 | 2023-03-10 | 2023-03-14 |
| DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia Dextenza 0.4Mg Ophthalmic Insert, Pred Forte - Vitreoretinopathy, Coats' Disease | Early Phase 1 | Completed | Lejla Vajzovic, MD, FASRS | 15 | 2023-02-01 | 2026-04-23 |
| Safety and Effectiveness of Drop-free Small Incision Cataract Surgery Intraoperative delivery of medication, Kenalog (Triamcinolone), Topical post-operative eyedrops, Prednisolone acetate - Cataract, Ocular Inflammation | Not applicable | Unknown | Visualiza | 100 | 2022-10-01 | 2022-08-09 |
| Dropless Pars Plana Vitrectomy Study Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin - Rhegmatogenous Retinal Detachment | Phase 4 | Completed | Massachusetts Eye and Ear Infirmary | 168 | 2022-07-25 | 2026-09-18 |
| The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer Docetaxel, Prednisolone Acetate, Platinum-based drugs - Hormone Sensitive Metastatic Prostate Cancer, DNA Damage Repair Deficiency | Phase 2 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 50 | 2022-07-01 | 2022-10-24 |
| Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp - Cataract Diabetic, Macula Edema | Phase 4 | Withdrawn | Baylor Research Institute | 2021-08-31 | 2026-03-02 | |
| In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery Dextenza 0.4Mg Ophthalmic Insert, Topical prednisolone acetate - Cataract | Phase 4 | Completed | Vance Thompson Vision | 30 | 2021-08-23 | 2025-08-17 |
| Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate - Dry Eye Syndromes | Phase 4 | Unknown | Sight Medical Doctors PLLC | 30 | 2021-04-26 | 2021-04-28 |
| Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate - Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | Phase 4 | Terminated | Retina Vitreous Associates of Florida | 10 | 2020-12-09 | 2023-02-22 |
| PREFERENTIAL Study Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE] - Cataract Surgery, Glaucoma Surgery | Phase 2 / Phase 3 | Withdrawn | Duke University | 2020-11-01 | 2021-11-17 | |
| Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp - Corneal Edema, Corneal Defect | Phase 4 | Completed | Nicole Fram M.D. | 36 | 2020-10-16 | 2023-07-24 |
| DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses Dexamethasone, Prednisolone Acetate 1% Oph Susp - Cataract | Phase 4 | Completed | Prism Vision Group | 13 | 2020-10-01 | 2023-06-22 |
| The Effectiveness and Safety of FK-506 for the Treatment of Posner-Schlossman Syndrome FK-506 (Drug), Prednisolone Acetate 1% Oph Susp - Posner Schlossman Syndrome | Not applicable | Unknown | Peking University | 30 | 2020-10-01 | 2021-08-16 |
Showing 20 of 78. Sign in to see all of them.
Cataract (22) · Macular Edema (6) · Glaucoma (5) · Inflammation (5) · Keratoconus (4) · Uveitis (4) · Uveitis, Anterior (4) · Conjunctivitis, Allergic (3) · Corneal Edema (3) · Dry Eye Syndromes (3) · Diabetes Mellitus, Type 1 (2) · Diabetes Mellitus, Type 2 (2) · Dilatation, Pathologic (2) · Eye Infections (2) · Eye Pain (2)
Alcon Research (4) · Bausch & Lomb Incorporated (4) · Innovative Medical (4) · Bp Consulting, Inc (2) · Carolina Eyecare Physicians, LLC (2) · Cxlusa (2) · Merck Sharp & Dohme LLC (2) · Nicole Fram M.D. (2) · Novartis (2) · Sight Medical Doctors PLLC (2) · VivaVision Biotech, Inc (2) · Aciont Inc (1) · Aldeyra Therapeutics, Inc. (1) · Allergan (1) · Aravind Eye Care System (1)
United States (55) · China (8) · France (4) · Germany (4) · Argentina (3) · Australia (3) · Italy (3) · Poland (3) · South Korea (3) · Taiwan (3) · Brazil (2) · Chile (2) · Greece (2) · India (2) · Israel (2)
William Trattler, MD (4) · John Hovanesian, MD (3) · Tim McNamara, PharmD (3) · Alanna Nattis, DO (1) · Audrey Rostov, MD (1) · Austin Bach, DO (1) · Baoping Xu (1) · Binu Alexander, MD (1) · Bonnie Henderson, MD (1) · C.Stephen Foster, MD, FACS, FACR (1) · Chun Zhang, PHD,MD (1) · Daniel Goodman, MD (1)
PMID 11152054, PMID 14078870, PMID 14078872, PMID 18599019, PMID 20809807, PMID 21704965, PMID 24677110, PMID 25062336, PMID 25880685, PMID 29650362, PMID 32557558, PMID 32882429, PMID 32955967, PMID 33035457, PMID 34996516, PMID 35067660, PMID 37532250, PMID 37981564, PMID 39563886, PMID 40630265, PMID 6514289
2025 (1), R44EY014772 (1)